An Early Phase 1 interventional study of AZD8529 and Placebo to match AZD8529 in Healthy and Memory Impairment, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-04.
Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science
The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).
269 studies on the registry are indexed under Memory Disorders; 62 are open to participants now.
This study's planned enrollment of 20 is below the median of 71 across 214 interventional studies indexed under Memory Disorders.
Browse Memory Disorders studies →AstraZeneca is the lead sponsor of 3,492 studies on the registry; 266 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 176 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
180 mg of AZD8529
Drug: AZD8529 · Drug: Placebo to match AZD8529
50 mg AD8529
Drug: AZD8529 · Drug: Placebo to match AZD8529
Placebo
Drug: AZD8529 · Drug: Placebo to match AZD8529
6 capsules by mouth 1 time 12 to 24 prior to assessments
6 capsules by mouth 1 time 12 to 24 hours prior to assessments
fMRI
Time frame: 3
Ketamine Infusion
Time frame: 3
Clinician Administered Dissociative States Scale (CADSS)
Positive and Negative Syndrome Scale (PANSS)
Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD8529